Photons and electrons one-on-one

The dynamics of electrons changes ever so slightly on each interaction with a photon. Physicists have now measured such interplay in its arguably purest form — by recording the attosecond-scale time delays associated with one-photon transitions in an unbound electron.

The photoelectric effect, whereby photons impinging on matter cause the emission of electrons, is one of the quintessential effects of quantum mechanics. Einstein famously explained the key mechanism underlying the phenomenon in 1905, earning him the 1921 Nobel Prize in Physics. He built on a concept introduced merely five years earlier by Max Planck: electromagnetic energy is absorbed and emitted only in discrete packets — that is, in quanta. The quantum concept revolutionised physics. The photoelectric effect, for its part, has been explored in ever greater detail, and is nowadays exploited in applications ranging from solar cells to night-vision goggles. A shift in our understanding of the effect came in the past decade or so. Laser experiments made it possible to look directly at the intricate quantum dynamics that unfold at the attosecond timescale as electrons are removed from their parent system when they interact with light. However, time-resolved measurements of the photoionization process in its arguably purest form — the absorption and emission of single photons by a single unbound electron — remained elusive. Until now.

Writing in the journal Optica, Jaco Fuchs and colleagues in the Ultrafast Laser Physics group of Prof. Ursula Keller at the Institute of Quantum Electronics, working with collaborators in the US, Austria and Spain, report an experiment in which they measured for the first time how the absorption and emission of single photons alters the dynamics of an electron that is not bound to an atomic nucleus, but still feels its Coulomb potential. Introducing a novel experimental protocol, they found that the dynamics depends on the angular momentum of the photoionized electron: they measured a delay of up to 12 attoseconds between outgoing s- and d-electrons in helium. This is a subtle yet unmistakable signature of underlying quantum-mechanical effects. And they observed fundamental phenomena of classical origin, too: they measured phase changes that reflect that in d-electrons the outward propagation is slower than in s-electrons. This can be explained by the larger fraction of rotational energy and hence a lower radial energy in d-electrons.

Extracting the contribution of single photons

These results mark several ‘firsts’. The Keller group has pioneered various areas of attoscience, including the measurement of attosecond time delays in photoionsation, which arise as photoexcited electrons propagate in the potential of the parent ion, resulting in a measurable group delay. The measurement of these attosecond-scale time delays typically involves at least two photons, making it exceptionally difficult to extract the contribution of single photons. Fuchs et al. now found a way to do just that.

In their case two photons are involved too, one in the extreme ultraviolet (XUV) and the other in the infrared (IR) range. But they devised a fitting procedure that enabled them to extract from their high-quality data the amplitudes and relative phases of all the quantum pathways through which photoionsation proceeds in their system. In this way they were able to isolate the different contributions of the IR photons, which are the ones inducing transitions in an unbound electron (whereas the XUV photons ionise the atom, by transferring an electron from a bound state to the continuum).

Direct measurement of delays arising from Bremsstrahlung

Not only did the ETH physicists gain for the first time access to time delays from any one-photon transition. Theirs are also the first measurements of such time delays for the absorption and emission of photons by unbound electrons, a phenomenon known as (inverse) Bremsstrahlung. The experimental results are well reproduced by two independent theoretical methods Fuchs and colleagues employed. These simulations also provide evidence that some of the observed effects are universal, in the sense that they are independent of the atomic species of the parent ion.

This work illustrates that also 115 years after Einstein’s seminal work, the photoelectric effect does not cease to inspire. The tools introduced by Fuchs and co-workers provide new experimental capabilities for studying photoionization dynamics, both in atoms and in small molecules. Such studies could in turn provide a fuller understanding of photoemission time delays, in particular in the presence of interactions in the intermediate-to-long range.

Story Source:

Materials provided by ETH Zurich Department of Physics. Note: Content may be edited for style and length.

Share Button

Epigenetic inheritance: A silver bullet against climate change?

The current pace of climate change exceeds historical events by 1-2 orders of magnitude, which will make it hard for organisms and ecosystems to adapt. For a long time, it has been assumed that adaptation was only possible by changes in the genetic makeup — the DNA base sequence. Recently, another information level of the DNA, namely epigenetics, has come into focus.

Using a fish species from the Baltic Sea, the three-spined stickleback, an international team investigated whether and how epigenetics contributes to adaptation. “Our experiment shows that epigenetic modifications affect adaptation, but also that the changes from one generation to the next are smaller than previously assumed,” says biologist Dr. Melanie Heckwolf from GEOMAR Helmholtz Centre for Ocean Research Kiel. She is one author of the study, which has now been published in Science Advances.

But what distinguishes changes in DNA from changes in epigenetics? “Individuals with certain heritable traits encoded in the DNA can cope with the prevailing environment better than others. On average, those individuals can cope better with their environment, hence survive longer and produce more offspring. In the long run, their characteristics encoded in the DNA will prevail. This process refers to natural selection,” explains Dr. Britta Meyer from GEOMAR. However, selection requires time, and time is scarce in the face of rapid climate change.

In contrast, epigenetic processes chemically influence the structure of the DNA. They activate or deactivate areas of the genome that are responsible for certain traits or responses to environmental conditions. On the one hand, “stable” epigenetic markers, through natural selection, contribute to adaptation in a similar way as the DNA itself. On the other hand, “inducible” markers are those that can change during the life of an individual. In theory, if this happens in the gametes of the parents, their offspring are given an advantage to cope with their environment. Many scientists therefore expect that inducible markers will react particularly quickly and thus ensure the survival of organisms in the face of rapid changes.

The research groups of Prof. Dr. Thorsten Reusch (GEOMAR, Germany) and Dr. Christophe Eizaguirre (Queen Mary University of London, UK) have investigated whether and how these stable and inducible markers contribute to adaptation. They use the Baltic three-spined stickleback fish because it is currently adapted to different salinity conditions ranging from saltwater to freshwater. Further, the Baltic Sea is a natural laboratory for climate change research because the effects of climate change are already evident there.

“In order to understand how fish respond to the consequences of climate change, we collected stickleback populations from different regions of the North and Baltic Seas with different salinity levels,” explains Dr. Meyer. The team found that the different populations differed in their genetic and epigenetic makeups and also had different tolerances to changes in salinity. In an experiment involving two generations of sticklebacks, the team was also able to show that inducible markers improve the response of the second generation to environmental change, albeit to a lesser extent than initially assumed.

Overall, the study shows that organisms will eventually reach their limits to respond to climate change, even with epigenetic modes of adaptation. “We have to be careful not to overinterpret this exciting but poorly understood field of research in epigenetics as a silver bullet against climate change for all species,” says Melanie Heckwolf. “Climate change is one of the greatest challenges for species and ecosystems, and the natural mechanisms available to species to respond may not be sufficient if climate change remains so strong and rapid.”

Story Source:

Materials provided by Helmholtz Centre for Ocean Research Kiel (GEOMAR). Note: Content may be edited for style and length.

Share Button

How to get conductive gels to stick when wet

Polymers that are good conductors of electricity could be useful in biomedical devices, to help with sensing or electrostimulation, for example. But there has been a sticking point preventing their widespread use: their inability to adhere to a surface such as a sensor or microchip, and stay put despite moisture from the body.

Now, researchers at MIT have come up with a way of getting conductive polymer gels to adhere to wet surfaces.

The new adhesive method is described in the journal Science Advances in a paper by MIT doctoral student Hyunwoo Yuk, former visiting scholar Akihisa Inoue, postdoc Baoyang Lu, and professor of mechanical engineering Xuanhe Zhao.

Most electrodes used for biomedical devices are made of platinum or platinum-iridium alloys, Zhao explains. These are very good electrical conductors that are durable inside the moist environment of the body, and chemically stable so they do not interact with the surrounding tissues. But their stiffness is a major drawback. Because they can’t flex and stretch as the body moves, they can damage delicate tissues.

Conductive polymers such as PEDOT:PSS, by contrast, can very closely match the softness and flexibility of the vulnerable tissues in the body. The tricky part has been getting them to stay attached to the biomedical devices they are connected to. Researchers have been struggling for years to make these polymers durable in the moist and always-moving environments of the body.

“There have been thousands of papers talking about the advantages of these materials,” Yuk says, but the companies that make biomedical devices “just don’t use them,” because they need materials that are exceedingly reliable and stable. A failure of the material could require an invasive surgical procedure to replace it, which carries additional risk for the patient.

Stiff metal electrodes “sometimes harm the tissues, but they work well in terms of reliability and stability over a period of years,” which has not been the case with polymer substitutes until now, he says.

Most efforts to address this problem have involved making significant modifications to the polymer materials to improve their durability and their ability to adhere, but Yuk says that creates problems of its own: Companies have already invested heavily in equipment to manufacture these polymers, and major changes to the formulation would require significant investment in new production equipment. These changes would be for a market that is relatively small in economic terms, though large in potential impact. Other approaches that have been tried are limited to specific materials. Instead, the MIT team focused on making the fewest changes possible, to ensure compatibility with existing production methods, and making the method applicable to a wide variety of materials.

Their method involves an extremely thin adhesive layer between the conductive polymer hydrogel and the substrate material. Though only a few nanometers thick (billionths of a meter), this layer turns out to be effective at making the gels adhere to any of a wide variety of commonly used substrate materials, including glass, polyimide, indium tin oxide, and gold. The adhesive layer penetrates into the polymer itself, producing a tough, durable protective structure that keeps the material in place even when exposed for long periods to a wet environment.

The adhesive layer can be applied to the devices by a variety of standard manufacturing processes, including spin coating, spray coating, and dip coating, making it easy to integrate with existing fabrication platforms. The coating the researchers used in their tests is made of polyurethane, a hydrophilic (water-attracting) material that is readily available and inexpensive, though other similar polymers could also be used. Such materials “become very strong when they form interpenetrating networks,” as they do when coated on the conducting polymer, Yuk explains. This enhanced strength should address the durability problems associated with the uncoated polymer, he says.

The result is a mechanically strong and conductive gel that bonds tightly with the surface it’s attached to. “It’s a very simple process,” Yuk says.

The bonding proves to be highly resistant to bending, twisting, and even folding of the substrate material. The adhesive polymer has been tested in the lab under accelerated aging conditions using ultrasound, but Yuk says that for the biomedical device industry to accept such a new material will require longer, more rigorous testing to confirm the stability of these coated fibers under realistic conditions over long periods of time.

“We’d be very happy to license and put this technology out there to test it further in realistic situations,” he says. The team has begun talking to manufacturers to see “how we can best help them to test this knowledge,” he says.

“I think this is a great piece of work,” says Zhenan Bao, a professor of chemical engineering at Stanford University, who was not associated with this research. “Wet adhesives are already a big challenge. Conductive adhesives that work well in wet conditions are even more rare. They are very much needed for nerve interfaces and recording electrical signals from the heart or brain.”

Bao says this work “is a major advancement in the bioelectronics field.”

Share Button

Coronavirus: Young people are not ‘invincible’, WHO warns

Youth does not make you immune from coronavirus, the UN’s health body warns as deaths top 11,000.

Share Button

Health24.com | WHO not against using ibuprofen for Covid-19 symptoms, but recommends paracetamol as a safer option

Earlier this week, the World Health Organization (WHO) recommended that people suffering Covid-19 symptoms avoid taking medication with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This suggestion came after French Health Minister, Olivier Veran, tweeted that, based on a study in the The Lancet medical journal, anti-inflammatory medications could worsen Covid-19 infections.

However, the WHO have since updated their advice, saying that they do not recommend against the use of the medication. This was based on currently available information, they said.

According to Science Alert, WHO spokesman Christian Linmeier said that the UN health agency’s experts were looking into the concern and are seeking to give further guidance on the matter.

“Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to relieve symptoms of headaches, painful periods, sprains and strains, colds and flu, arthritis, and other causes of long-term pain,” explains the NHS website. 

Panic and confusion following study’s release

When French Minister Veran tweeted that anti-inflammatories such as ibuprofen can be “an aggravating factor” in Covid-19 infections this week, panic ensued and discussions among medical experts quickly followed. The Lancet study he referred to hypothesised that an enzyme, boosted by anti-inflammatory drugs could consequently aggravate Covid-19 infections.

But experts say that currently, there’s simply not enough evidence to warrant this as a conclusion.

“There is currently no scientific evidence establishing a link between ibuprofen and worsening of Covid-19,” the European Medicines Agency (EMA) wrote in a statement on 18 March, reports LiveScience.

“The only problem is they [researchers] offer no proof that this actually occurs,” Angela Rasmussen, a virologist at Columbia University in New York, explained on Twitter. “And this hypothesis relies on several major assumptions that may not be true.”

Instead, the severity of the disease is dependent on many other factors such as the patient’s genetics and general health, Rasmussen added.

To use or not to use?

The NHS has said that while there is no firm evidence that NSAIDs can worsen Covid-19 symptoms, until more credible information becomes available, they advise to err on the side of caution and take paracetamol to treat the symptoms of the new coronavirus instead – unless your doctor advises against its use, reports the BBC. 

NSAIDs and possible side effects

Although NSAIDs are commonly used, they’re not suitable for everyone – and can sometimes cause upsetting side effects, notes the NHS, especially for people with asthma and heart problems.

There are some studies that have found a link between NSAIDs causing complications and severe illness in other respiratory infections, and may “dampen” the body’s immune system, medical experts told the BBC. 

However, Professor Parastou Donyai at the University of Reading also told the news broadcasting company: “I have not seen any scientific evidence that clearly shows a totally healthy 25 year old taking ibuprofen for symptoms of Covid-19 is putting themselves at additional risk of complications.”

For this reason, it’s safe to assume that, according to medical professionals, if you are already taking medications with anti-inflammatory properties for other conditions, you should not stop without consulting their doctor. 

With regard to the topic at hand, until rigorous research on NSAIDs having an effect on the severity of illness caused by the new coronavirus, in both healthy people and those with chronic conditions, becomes available, Linmeier has recommended rather using paracetamol, and not to use ibuprofen as a self-medication.

Similarly, Dr Charlotte Warren-Gash, associate professor of epidemiology at London School of Hygiene and Tropical Medicine, has advised particularly vulnerable patients that “it seems sensible to stick to paracetamol as first choice.”

READ MORE | Bill Gates warned of an impending epidemic that would affect the world – he was chillingly accurate

READ MORE | How long can coronavirus survive in the air and on surfaces; and why do you need to wash your hands?

READ MORE | Coronavirus in SA: All the confirmed cases

Image: Ana Maria Serrano/Getty

Share Button

The Elephant and the Virus

With respect to the coronavirus pandemic, I am concerned about India. Given their population density and more than 1.3 billion residents, the virus situation there could soon make what’s happening in Italy and Spain look tame.

Earlier this week India was reporting only 129 infections and 2 deaths. Today it’s at 249 cases and 5 deaths. While those numbers may seem ridiculously low relative to India’s population, they appear to be starting out much the same as any other country.

While mathematical illiterates might dismiss these numbers as trivial, fortunately India’s Prime Minister and their National Security Council are paying serious attention to what’s happening elsewhere. Consequently, India has been on lockdown since March 18 and plans to continue through March 31. I think they’ll need significantly longer, but it’s good to see them taking this step.

India’s director of the Center for Disease Dynamics, Economics, and Policy, Dr. Ramanan Laxminarayan, warns that India may have to deal with a tsunami of about 300 million coronavirus cases. He estimates that India has 70K-100K ICU beds in the entire country. Note that the total ICU beds in the USA are also estimated to be in this same range, and the USA is already on a path to overflow these beds in the weeks ahead but with a billion fewer people.

One of my concerns is that India may be severely under-testing. So I’d pay a lot more attention to the death count than to the infections reported and watch what that number does in the weeks ahead. When testing is weak, deaths are more likely to be noticed than infections, especially as more people who are struggling to breathe seek medical care.

If you look at other countries with death totals close to India’s, many are reporting significantly more infections. Austria, Denmark, Norway, Malaysia, and Portugal all report 3-7 coronavirus deaths so far, and their reported infections range from 1020 to 2491. Now there are lots of other countries with similar death totals but with lower infection counts closer to India’s, and by and large these are countries where testing appears to be very limited.

Since the death numbers are so low, they may not be significant right now, but this is something for people in India to watch carefully in the weeks ahead.

Note that just 25 days ago on February 24, Italy was at 229 reported cases and 7 deaths, which is very close to where India is today. Now Italy is at 47,021 cases and 4032 deaths – 5986 of those cases and 627 of those deaths in the last 24 hours – and still rising faster and faster. Also note that India’s population is 22 times the size of Italy’s.

That said, I am seeing solid evidence that India is being a lot more intelligent and cautious about this virus than many other countries. They’re way ahead of the USA, getting to lockdown much sooner. In the U.S. the inevitable lockdown is unfolding on a state by state and even city by city basis. California just went into statewide lockdown last night. Other U.S. states will soon follow. Slow-rolling a countrywide lockdown instead of going there immediately means more people will suffer and die, including more medical staff. This should be coordinated at the federal level like India has done. The leadership void at the top means that state governors have to step up now more than ever to help compensate as best they can.

Many countries are seeing their infections and deaths ramp up tremendously, and this will go considerably higher in the weeks ahead as we go higher up the exponential growth curve. In time this will reveal the price each country pays for underestimating this virus.

While practicing social distancing and going into lockdown are key steps that will save many lives, abundant testing is crucial as well to understand what’s happening and to know if measures are being effective or if more is needed.

One key risk I’m seeing in India is overconfidence. This is an easy trap to fall into when the numbers are still low and especially when you’re already in lockdown and practicing social distancing. While it’s commendable that India has implemented serious measures sooner than most, there’s still a potent risk of falling into the overconfidence trap by assuming that it’s enough.

Moreover, compliance can be a real problem too. In my home state of Nevada, we’re under partial measures for at least 30 days. The hotels and casinos are closed statewide, which hasn’t happened since President Kennedy’s assassination in 1963, and that was only one day of closure back then. As extreme as this may seem, especially for the 206K casino employees who are out of work now, we’re still just stair-stepping our way towards a full lockdown. Meanwhile it’s being reported that non-essential businesses remain open, including some restaurants and retail stores. Some businesses are still telling their employees to come into work, even where people must work in close proximity to each other, and the employees feel they have to show up because they don’t want to lose their jobs. Some will lose their lives because of it. So the existing directives aren’t being complied with yet. In fact, the Vegas police have been getting so many phone calls about these violations of the Governor’s order that they’re telling people to stop calling to report such businesses.

Even with really good government measures in place, the practical reality of this situation is that when we think we’re doing enough, it’s more likely that we’re being overconfident and not being cautious enough.

The challenge this virus presents is that in order to get aligned with its behavior and respond appropriately, we must consistently do more than we think is necessary, which is an uncomfortable place to be. When we think we’ve finally implemented what’s necessary and can settle in at that level because surely it’s enough now, we’ve succumbed to overconfidence, and the virus will make additional gains because of that, including overwhelming hospitals and medical staff.

So in this case, it’s good to feel like you’re overdoing it by being more cautious than you think is necessary. It’s also good to feel like you’re taking more social risk than usual to rein in sociopathic behavior.

The most caring and compassionate people I know are feeling very socially uncomfortable these days; they’re all getting some social blowback because they’re stretching themselves to do what it takes to save lives and reduce suffering. They can see plain as day that it’s the right response under the circumstances though. When they get overwhelmed, they do whatever they need to do to recharge, to accept reality, and to forgive, and they go right back into the fray. Heroes all of them. The people who’s lives they save may never know it, and the work they’re doing is largely thankless, but I want them to know that I personally appreciate and applaud their efforts.

Under current circumstances, the torrent of vitriol that was unleashed upon the Floridiot Governor for permitting spring breakers to crowd the beaches earlier this week was an appropriate response to sociopathic behavior. And it was effective. That Governor quickly caved to the onslaught of social and political pressure and shut those beaches down.

At the national and individual levels, we all need to stretch ourselves further into the zone of discomfort. For the next several weeks at least, we need to bid enoughness adieu and embrace the discomfort of toomuchness.

Perhaps India has achieved enoughness in their response, which may impress some humans but isn’t enough to earn the respect of this virus. This virus eats American enoughness for breakfast, Spanish enoughness for lunch, and Italian enoughness for dinner. And presently it seems to be developing an appetite for British enoughness at tea time. Along with the rest of us, India’s challenge is to push further into toomuchness and stay there for a while. Maybe they can teach this virus a thing or two about fasting.

Share Button

Health24.com | Preemies’ impaired immune systems quickly catch up

Premature infants’ immune systems develop at a rate similar to full-term infants, a new study finds.

British researchers tracked immune system development in babies born before 32 weeks, including identifying different immune cell populations and the types of bacteria present in stool samples.

All of the preemies’ immune systems progressed similarly as they got older, regardless of how early they were born.

Babies born after the shortest gestation – earlier than 28 weeks – had a greater degree of immune system progress over a similar time period than those who spent more time in the womb.

Environment after birth

The findings suggest that preterm and full-term infants’ immune system development follows a set pattern after birth, according to the study authors.

“These data highlight that the majority of immune development takes place after birth and, as such, even those babies born very prematurely have the ability to develop a normal immune system,” said study author Deena Gibbons, a lecturer in immunology at King’s College London.

Infection and related complications are significant causes of death among premature babies, but researchers said there is limited understanding of how their immune systems develop and how that can be influenced by the environment after birth.

Researchers also found that some preterm babies who developed infection had reduced CXCL8 (interleukin 8)-producing T-cells at birth. T-cells play a key role in immune response to infection.

Improving outcomes

The finding suggests that infants at risk of infection and complications in the first few months of life could be identified shortly after birth, which may improve their outcomes.

“We are continuing to study the role of the CXCL8-producing T-cell and how it can be activated to help babies fight infection,” Gibbons said in a university news release. “We also want to take a closer look at other immune functions that change during infection to help improve outcomes for this vulnerable group.”

The findings were published in the journal Nature Communications.

Image credit: iStock

NEXT ON HEALTH24X

Share Button

Social distancing may be needed for ‘most of year’

The government’s scientific advisers say this will help to limit the spread of coronavirus.

Share Button

Coronavirus: Tens of thousands of retired medics asked to return to NHS

More than 65,000 ex-doctors and nurses are asked to help tackle the “greatest global health threat in history”.

Share Button

Health24.com | The new coronavirus: The urgent, but long race for a vaccine

The virus which causes Coronavirus Disease 2019 (Covid-19), has been spreading rapidly globally, putting pressure on vaccine and drug developers to invent new products to stop infections and save lives.

The desperate need for a vaccine to curb the respiratory infection is driving research and development, with more than 24 companies estimated to be in the race. Vaccines are entering human clinical trials much faster than ever before. 

Apart from the life-saving impact of an effective Covid-19 virus vaccine, these new technologies and approaches are expected to also inform future scientific research on badly needed vaccines for HIV and tuberculosis. 

First vaccine trial underway

In the first human clinical trial to protect against the Covid-19 virus, four volunteers were injected with a candidate vaccine in Seattle in the United States earlier this week, according to the Kaiser Permanente Washington Health Research Institute. Start-up biotechnology company Moderna Inc. set a drug industry record by identifying their candidate vaccine in only 42 days after the Covid-19 virus was sequenced. 

In total, 45 young, healthy men and women, between 18 and 55 years, enrolled in the US National Institutes of Health-funded clinical trial. The volunteers will get different doses of the vaccine in order to establish the safety of different doses.

The objective of this first trial is only to find out if the potential vaccine called mRNA 1273 is safe and does not have any serious adverse events (side effects). If things go well, further larger trials will be conducted. 

Even if all goes to plan, the vaccine will only be ready for use in 12 to 18 months.

The vaccine is made using a new process that is much faster than older methods. It doesn’t contain any part of the virus itself as is the case in most vaccines. Instead, it includes a short segment of so-called messenger RNA that is made in a lab and is designed to stimulate human cells to produce a viral protein, to which the body would develop a protective antibody response. 

Other contenders 

Another company called Inovio Pharmaceuticals has a DNA vaccine it says can generate protective antibodies to shield people from infection with coronavirus. Human testing of their vaccine called INO_4800 is expected to start later this year. Development from there is likely to follow a similar 12 to 18 month timeline.

Researchers at the Precision Vaccines Programme (PVP) at America’s Boston Children’s Hospital are on the frontline of developing a vaccine which specially targets older populations.

According to the hospital’s website, the current antigen used for vaccine development is the coronavirus spike protein, named because it sits on top of the spike of a coronavirus particle. This is the part of the virus that the immune system “remembers”. Vaccine-induced antibodies, made by the immune system against the spike protein, can prevent infection.

PVP’s strategy, it says, is to combine the coronavirus spike protein with adjuvants: small molecules added to a vaccine to boost the recipient’s immune response. Adjuvants can be crucial for getting a stronger, longer-lasting, broader immune response, especially among those with weakened immunity, like the elderly.

The Gates Foundation, a major medical research funder, is spreading its bets among several cutting-edge vaccine platforms, including those using genetic material and the ones based on synthetic biology that hold promise. 

Relevance for potential HIV and TB vaccines

Professor Willem Hanekom, Director of the African Health Research Institute (AHRI) in KwaZulu-Natal (KZN) said traditional vaccines have taken a long time to be developed. For example, the new M72 vaccine in development to fight TB has taken about 15 years to reach currently planned efficacy trials. The trial of the M72 subunit vaccine developed by GSK, contains a fragment of the bacterium to stimulate an immune response and has been the only new vaccine, so far, showing protection against TB disease in vaccine trials.

Hanekom says the new approaches will “undoubtedly” be used in vaccine development for HIV and TB but there are still some significant “unknowns” which complicate things. “For some viruses like Ebola and Covid-19, it may be easier to predict which proteins need to be included in the vaccine, as immune response to these proteins is likely to be associated with protection.” 

As with the Moderna Inc. coronavirus candidate, he says, “You can make a piece of synthetic RNA which encodes for a protein that elicits an immune response, associated with protection.” The same, he says, could be achieved with the HI virus and the TB bacterium if “we knew which proteins are linked to protection, but we don’t have a full understanding of this at the moment”. So, while these technologies can be used it’s not as simple with HIV and TB.

For Hanekom, the number one research question is what impact the new coronavirus will have on immuno-compromised South Africans. AHRI does research on prevention of HIV and TB transmission and non-communicable diseases in Somkhele, in northern KZN, which has a high HIV prevalence of 38%. Would people with HIV do worse if infected with the novel coronavirus?

He says surveillance needs to be done to find out. In comparison to Italy whose demographics are skewed toward older people, South Africa with a younger population may be at an advantage when it comes to coronavirus morbidity and mortality. The WHO has said that infected elderly people are most at risk of dying as well as those with underlying chronic illnesses.

Regarding TB Hanekom says, people with chronic lung disease are at risk of developing more severe Covid-19. “We don’t yet know if people with lung disease associated with current or previous TB are at greater risk of Covid-19, but it is likely,” he said.

‘South Africa needs a break’

Heroes Director of the Desmond Tutu HIV Centre, Professor Linda-Gail Bekker, says unlike SARS which came and went, the new coronavirus is likely to be endemic and there will be a need for a vaccine in the short and long term. She said HIV is “tricky”, but new technologies are already opening up new possibilities. Johnson and Johnson’s so-called HIV mosaic concept trial is based on a synthetic approach. 

Meanwhile scientists in Australia have reported that medicines (not vaccines) to treat HIV and malaria could be used to tackle coronavirus. Infectious disease experts at the University of Queensland in Brisbane report that Chloroquine, an anti-malarial drug, and an HIV-suppressing combination lopinavir/ritonavir have both shown promising results in human tests and made the virus “disappear” in infected patients.

Bekker said a good research question would be to see if Chloroquine can be used prophylactically and as treatment for people co-infected with HIV and the Covid-19 virus. 

In addition, she said there is also discussion in South Africa on being part of the pharmaceutical company Gilead’s trial of the experimental medicine remdesivir, an intravenous treatment, which has already been used to treat an infected patient in the United States. Gilead is recruiting around 1 000 patients with Covid-19 for large-scale studies in Asia, to find out whether multiple doses of remdesivir can reverse infection.

Bekker praised volunteers in current and future clinical trials for a coronavirus vaccine and treatment as “heroes”. “We are holding our breath that all measures will flatten the infection curve. “South Africa needs a break!”

*Adele Baleta is an independent science writer, media consultant and facilitator

*This article was produced for Spotlight – health journalism in the public interest.

Image credit: iStock

Share Button